Comparative Pharmacology
Head-to-head clinical analysis: CYCLAPEN W versus DURACILLIN A S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAPEN W versus DURACILLIN A S.
CYCLAPEN-W vs DURACILLIN A.S.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has a similar spectrum to ampicillin but with increased acid stability and oral absorption.
Penicillin G procaine is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
600,000 units intramuscularly once daily; or 1.2 million units intramuscularly every 12 hours for severe infections.
None Documented
None Documented
0.5-1 hour in adults with normal renal function; prolonged to 2-6 hours in renal impairment.
0.5-1 hour in adults with normal renal function; prolonged to 7-10 hours in end-stage renal disease
Primarily renal (90-100% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Primarily renal (60-90% unchanged via tubular secretion and glomerular filtration); minor biliary/fecal elimination (<10%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic